The present invention provides for methods of epigenetic analysis. In some cases, the methods may include obtaining a sample comprising a nucleic acid sequence. In some cases, the nucleic acid sequence may comprise one or more epigenetic marks. The methods may include performing a sequencing. The methods may include distinguishing a hydroxymethylated base from a methylated base.

The present invention provides for methods of epigenetic analysis. In some cases, the methods may include obtaining a sample comprising a nucleic acid sequence. In some cases, the nucleic acid sequence may comprise one or more epigenetic marks. The methods may include performing a sequencing. The methods may include distinguishing a hydroxymethylated base from a methylated base.

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.

The present invention provides cell-based assays, including high throughput cell-based assays, for identification of candidate therapeutic agents with the ability to inhibit microglial activation in vivo in response to different ligands.

Provided are a cell secreted-type amylospheroids-like structure, a drug and vaccine using the same, as well as a method of producing the same. In one aspect, the present disclosure relates to a production method including a step of culturing, in a culture medium, cells that express an amyloid precursor protein (APP) or a part thereof containing an amyloid beta-protein (Aß) sequence to obtain a cell secreted-type amylospheroids (ASPD)-like structure in said culture medium.

The present invention relates to methods of using bacterial strain 1687A6 in detecting, diagnosing and treating disease or disorders of the GI tract. The present invention also relates to modulating the immune responses of an individual by inducing Th17 cell differentiation, proliferation, or accumulation. Further, the invention relates to therapeutic compositions containing strain 1687A6 or compounds derived from it and methods for treating disease in a subject using such compositions.

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.

Apparatuses, systems and methods for using assay preparation plates comprising wells with two trenches are presented. More specifically, well plates are presented that comprising an array of wells configured to retain a plurality of beads suspended in a fluid during an assay procedure, each well in the array comprising a first trench and a second trench, wherein the working volume of each well is between about 25 uL and about 10 mL.